If you need more lookups,
subscriptions start at $34 USD/month.
Judit Bartis Location
Cambridge, MA, US
Judit Bartis Work
VP, CMC Operations @ (January 2024 - Present)
Vice President, Global Clinical Supply Management @ (April 2024 - October 2024)
Vice President Pharmaceutical Development @ Albireo Pharma, Inc. (Acquired by Ipsen in March, 2023) (April 2022 - April 2024)
Senior Director Drug Product Development @ (May 2019 - June 2021)
Senior Director, Drug Product Manufacturing and Devlopment @ Relypsa (March 2015 - May 2019)
Senior Advisor @ (February 2010 - January 2012)
Consultant @ (August 2009 - May 2011)
Director, CMC @ Pear Tree Pharmaceuticals (July 2008 - September 2009)
Manager, Formulation and Product Development @ (January 2006 - July 2008)
Associate Director @ (January 2003 - January 2005)
Senior Manager @ (January 2002 - January 2003)
Senior Scientist @ (September 1997 - January 2002)
Judit Bartis Education
D'Amore-McKim School of Business at Northeastern University
MBA
2001-2003
The City University of New York
PhD (Chemistry)
1992-1997
Judit Bartis Skills
Product Development
Formulation
Drug Discovery
Biotechnology
Pharmaceutical Industry
Technology Transfer
Drug Development
Lifesciences
GMP
Clinical Development
Oncology
Validation
Analytical Chemistry
HPLC
CRO
R&D
GLP
Biopharmaceuticals
LIMS
21 CFR Part 11
Leadership
Lean Manufacturing
Data Analysis
Business Analysis
Research
Judit Bartis Summary
Judit Bartis, based in Cambridge, MA, US, is currently a VP, CMC Operations at Aktis Oncology. Judit Bartis brings experience from previous roles at Ipsen, Albireo Pharma, Inc. (Acquired by Ipsen in March, 2023), Albireo Pharma, Inc. and Relypsa. Judit Bartis holds a 2001 - 2003 MBA @ D'Amore-McKim School of Business at Northeastern University. With a robust skill set that includes Product Development, Formulation, Drug Discovery, Biotechnology, Pharmaceutical Industry and more. Judit Bartis has 4 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Judit Bartis?
Find contact details for 700 million professionals.